

## **PMDs publishes information memorandum in connection with the forthcoming rights issue**

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

PMD Device Solutions AB ("PMDs" or the "Company") publishes today an information memorandum (the "Memorandum") in connection with the Company's forthcoming rights issue of shares of approximately SEK 27.5 million, which was announced by the Company on June 11, 2024, and resolved by the Company's board of directors on July 5, 2024 (the "Rights Issue"). The subscription period for the Rights Issue runs between August 19 – September 2, 2024. The Memorandum is available on the Company's website, [www.pmd-solutions.com](http://www.pmd-solutions.com), and on Nordic Issuing AB's website, [www.nordic-issuing.se](http://www.nordic-issuing.se).

The Memorandum, the application for subscription of shares with and without subscription rights and other information about the Rights Issue are available on the Company's website, [www.pmd-solutions.com](http://www.pmd-solutions.com), and on Nordic Issuing AB's website [www.nordic-issuing.se](http://www.nordic-issuing.se). The record date for receiving subscription rights was August 15, 2024. The subscription period for the Rights Issue runs between August 19 – September 2, 2024.

**Timetable for the Rights Issue, all dates referring to 2024:**  
<https://investors.pmd-solutions.com/en/rights-issue-2024/>

August 19 – September 2	The Subscription Period for the Rights Issue.
August 20 – August 28	Trading with subscription rights on Nasdaq First North Growth Market.
August 20	Trading with BTA commences. Trading continues until the Rights Issue has been registered with the Swedish Companies Registration Office, estimated to occur in week 38, 2024.
Around September 5	The announcement of the outcome of the Rights Issue is expected to be published.

Full terms and conditions of the Rights Issue and other information about the Company are provided in the Memorandum.

#### **Advisors**

Stockholm Corporate Finance AB is acting as financial adviser to the Company in the Rights Issue. Eversheds Sutherland Advokatbyrå AB is acting as the legal adviser to the Company. Nordic Issuing AB is the issuing agent in the Rights Issue.

#### **IMPORTANT INFORMATION**

This press release is not an offer to subscribe for shares in PMDS and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in PMDS will only be made through the Memorandum published by the Company.

This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions. Neither subscription rights, shares subscribed for ("BTA") or newly issued shares have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further prospectus is established, registered or that any other measure is undertaken beyond that required by Swedish law. The press release, as well as the prospectus, the application form and other documents attributable to the Rights Issue, may consequently not be distributed to any such jurisdiction.

There is no intention to register any portion of the offer in the United States and the securities issued in the Rights Issue will not be offered to the public in the United States.

The Company has not authorized any offer to the public with regards to the shares or rights that are referred to in this communication in any member state of the European Economic Area ("EEA") besides Sweden. This communication is only addressed to and is only directed at qualified investors in other members states within the EEA.

This press release may contain certain forward-looking information that reflects PMDS' current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. PMDS makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.

**For additional information, please contact**

---

Myles Murray, CEO

Phone: +353 86 887 4994

E-mail: [myles@pmd-solutions.com](mailto:myles@pmd-solutions.com) & for general enquiries [investor.relations@pmd-solutions.com](mailto:investor.relations@pmd-solutions.com)

The Company's Certified Adviser is Redeye.

**Information about PMDS**

---

PMD Device Solutions AB develops and sells medical products for respiratory monitoring in both the hospital acute monitoring sector and the remote monitoring homecare sector. Its primary product is RespiraSense, a solution used for monitoring respiratory rate to support the detection of patient deterioration early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense is, to the Company's knowledge, the world's only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. RespiraSense is a novel technology that is commercialised in Europe, the UK, and FDA cleared in the US. The company's shares are listed on Nasdaq First North Growth Market (STO: PMDS).

**Attachments**

---

**PMDS publishes information memorandum in connection with the forthcoming rights issue**